FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Fluvoxamine ER Capsules
Status: Currently in Shortage
»Date first posted: 02/05/2019
»Therapeutic Categories: Psychiatry

Expand all

Par Pharmaceutical (Revised 12/16/2019)

Company Contact Information:
800-828-9393, option 5 then option 2

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg. 30’s count (NDC 10370-175-11) On backorder. Estimated availability January 2020 Shortage of an active ingredient
150 mg. 30’s count (NDC 10370-176-11) On backorder. Estimated availability January 2020 Shortage of an active ingredient

Teva Pharmaceuticals (Reverified 01/15/2020)

Company Contact Information:
800-545-8800

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Fluvoxamine 100 mg Extended Release Capsules, 30 count (NDC 0228-2848-03) Available Other
Fluvoxamine 150 mg Extended Release Capsules, 30 count (NDC 0228-2849-03) Available Other

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English